Alx Oncology Holdings Inc (ALXO)

$8.98

+0.11

(+1.24%)▲

Market is closed - opens 8 PM, 29 Nov 2023

Insights on Alx Oncology Holdings Inc

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 76.9% return, outperforming this stock by 88.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 26.8% return, outperforming this stock by 113.9%

Performance

  • $8.61
    $9.18
    $8.98
    downward going graph

    4.12%

    Downside

    Day's Volatility :6.21%

    Upside

    2.18%

    downward going graph
  • $3.94
    $12.33
    $8.98
    downward going graph

    56.12%

    Downside

    52 Weeks Volatility :68.05%

    Upside

    27.17%

    downward going graph

Returns

PeriodAlx Oncology Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
111.69%
-2.6%
0.0%
6 Months
32.78%
2.2%
0.0%
1 Year
-11.92%
-4.3%
-3.4%
3 Years
-88.47%
19.1%
-4.7%

Highlights

Market Capitalization
488.2M
Book Value
$4.1
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.57
Wall Street Target Price
15.25
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-35.9%
Return On Equity TTM
-64.09%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
107.0K
EBITDA
-153.7M
Diluted Eps TTM
-3.57
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.61
EPS Estimate Next Year
-3.3
EPS Estimate Current Quarter
-0.87
EPS Estimate Next Quarter
-0.79

Analyst Recommendation

Buy
    84%Buy
    15%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Alx Oncology Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 69.82%

Current $8.98
Target $15.25

Technicals Summary

Sell

Neutral

Buy

Alx Oncology Holdings Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alx Oncology Holdings Inc
Alx Oncology Holdings Inc
28.92%
32.78%
-11.92%
-88.47%
-70.43%
Moderna, Inc.
Moderna, Inc.
4.93%
-38.23%
-55.68%
-49.12%
317.85%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
2.62%
9.54%
7.63%
54.66%
119.47%
Novo Nordisk A/s
Novo Nordisk A/s
7.75%
29.99%
71.36%
209.46%
351.9%
Seagen, Inc.
Seagen, Inc.
0.13%
10.52%
76.89%
25.9%
249.5%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.03%
7.65%
11.07%
53.76%
96.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alx Oncology Holdings Inc
Alx Oncology Holdings Inc
NA
NA
NA
-3.61
-0.64
-0.36
0.0
4.1
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.11
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.78
22.78
9.01
42.51
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.76
41.76
2.03
2.65
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.68
26.68
0.41
15.04
0.23
0.14
0.02
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alx Oncology Holdings Inc
Alx Oncology Holdings Inc
Buy
$488.2M
-70.43%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$29.8B
317.85%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$87.0B
119.47%
22.78
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$458.4B
351.9%
41.76
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.0B
249.5%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$91.4B
96.32%
26.68
35.94%

Institutional Holdings

  • venBio Partners LLC

    19.47%

  • FMR Inc

    12.31%

  • Vivo Capital, LLC

    8.47%

  • Orbimed Advisors, LLC

    5.76%

  • BlackRock Inc

    3.59%

  • Redmile Group, LLC

    2.58%

Corporate Announcements

  • Alx Oncology Holdings Inc Earnings

    Alx Oncology Holdings Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

alx oncology (previously alexo therapeutics) is a clinical-stage immuno-oncology company developing therapies that block the cd47 myeloid checkpoint mechanism exploited by cancer cells to evade the immune system. our lead candidate, alx148, is a fusion protein that comprises an engineered high affinity cd47 binding domain of sirpa linked to an inactive fc region of human immunoglobulin. alx148 is currently being investigated in a phase 1 study in combination with checkpoint inhibitors and targeted anti-cancer antibodies (nct03013218). for more information about the company, please visit our website at www.alxoncology.com

Organization
Alx Oncology Holdings Inc
Employees
71
CEO
Dr. Corey S. Goodman Ph.D.
Industry
Commercial Services

Discover More

FAQs